Search

Displaying results 3751 - 3760 of 7897 in total
  1. Drug

    OSU-6162

    go.drugbank.com/drugs/DB19178
    Investigational

    OSU-6162 is under investigation in clinical trial NCT05641623 (OSU6162 as Add-on in Ssri/snri-resistant Depression).

  2. Drug

    Sulopenem

    go.drugbank.com/drugs/DB15284
    Investigational

    Sulopenem is a penem antibacterial. It is marketed as the prodrug [sulopenem etzadroxil] in combination with [probenecid].[L51768]

  3. Drug

    IGN311

    go.drugbank.com/drugs/DB04988
    Experimental

    IGN311 is a humanized monoclonal antibody (mab) against the Lewis Y carbohydrate antigen, a blood-group-related oligosaccharide.

  4. Drug

    Shark liver oil

    go.drugbank.com/drugs/DB11088
    Approved

    Shark oil is a rich source of alkylglycerols and squalene, with relatively low amounts of n-3 polyunsaturated fatty acids. … The potential benefit of shark oil has been experimented in different therapeutic implications, where it is claimed to improve immune responses and exert an antitumor activity.

  5. Drug

    Siltuximab

    go.drugbank.com/drugs/DB09036
    ApprovedInvestigational

    It is administered as a 1 hour intravenous infusion every 3 weeks. … Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology.

  6. Drug

    EHT899

    go.drugbank.com/drugs/DB05108
    Experimental

    EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. … It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.

  7. Drug

    NS-398

    go.drugbank.com/drugs/DB14060
    Experimental

    NS-398 is a COX-2 inhibitor. It was developed as part of the mechanistic study of the cyclooxygenases.

  8. Drug

    MaaT013

    go.drugbank.com/drugs/DB18648
    Investigational

    MaaT013 is an allogeneic fecal microbiota therapy. It is being investigated for the treatment of Graft-Versus-Host Disease.

  9. Drug

    BB-1701

    go.drugbank.com/drugs/DB17443
    Investigational

    BB-1701 is a humanized IgG1 kappa monoclonal antibody (anti-HER2 antibody) conjugated to eribulin developed by Bliss Biopharmaceutical.

  10. Drug

    S64315

    go.drugbank.com/drugs/DB17559
    Investigational

    S64315 (MIK665) is an inhibitor of induced myeloid leukemia cell differentiation protein Myeloid cell leukemia 1 (Mcl-1).[A257311]